Antipsychotic polypharmacy increases metabolic dysregulation in female rats.
Antipsychotic polypharmacy refers to the clinical practice of treating a patient with two or more antipsychotic drugs concurrently. There is abundant evidence in the clinical literature that treatment with antipsychotic polypharmacy is associated with an increased prevalence of drug side effects compared with monotherapy. This includes drug-induced metabolic side effects, such as glucose intolerance and insulin resistance. As these metabolic side effects have been accurately modeled in preclinical rodent paradigms using drug monotherapy, the goal of the present study was to determine the metabolic effects of antipsychotic polypharmacy using an established rodent model. In the first experiment, adult female rats were treated with clozapine (5 mg/kg), risperidone (1 mg/kg), vehicle, or clozapine + risperidone. In the second experiment, rats were treated with clozapine (5 mg/kg), haloperidol (0.1 mg/kg), vehicle, or clozapine + haloperidol. Animals were then subjected to a glucose tolerance test. Compared with vehicle-treated control animals, risperidone and haloperidol had no effect on any of the metabolic indices when administered on their own. Addition of risperidone to clozapine significantly increased fasting glucose, fasting insulin, and insulin resistance compared with the clozapine-only group. The addition of haloperidol to clozapine significantly increased fasting insulin levels, insulin resistance, and glucose intolerance compared with clozapine-only rats. These results are consistent with clinical studies and therefore indicate that animal models can successfully be used to study the metabolic side effects of antipsychotic drugs. Future studies related to understanding the physiological mechanisms involved remain a priority.
Department of Anesthesiology, Pharmacology, & Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B.C., CANADA, V6T 1Z3.
Heidi N
HN
Boyda
Ric M
RM
Procyshyn
Lurdes
L
Tse
James
J
Xu
Chen Helen
CH
Jin
Daniel
D
Wong
Catherine C Y
CC
Pang
William G
WG
Honer
Alasdair M
AM
Barr
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008660:Metabolism / Q000187:drug effects*; D019338:Polypharmacy; D051381:Rats; D017207:Rats, Sprague-Dawley
D014150:Antipsychotic Agents; D007328:Insulin